Diagnosis of hepatitis C

Area of Science:

• Hepatology and Virology
• Clinical Diagnostics
• Infectious Disease Management

Background:

• Second- and third-generation enzyme immunoassays (EIA-2 and EIA-3) are standard for hepatitis C virus antibody (anti-HCV) screening.
• Polymerase chain reaction (PCR) assay for HCV RNA detection is the gold standard for diagnosing HCV infection, despite current assay variability.
• Confirmatory testing strategies for HCV infection depend on clinical context and initial screening results.

Framework:

• Confirmatory tests are often unnecessary for anti-HCV positive patients with chronic liver disease.
• Qualitative PCR for HCV RNA is the preferred confirmatory test when indicated.
• For anti-HCV positive blood donors and individuals with normal aminotransferase levels, confirmatory testing involves recombinant immunoblot assay (RIBA) followed by PCR for RIBA-positive or indeterminate results.

Implementation:

• Liver histology remains the gold standard for assessing liver disease severity.
• Quantitative HCV RNA levels are not currently useful for determining liver disease severity.
• HCV genotyping is considered a research tool, not a routine diagnostic procedure.

Implications:

• The primary goals of chronic hepatitis C treatment are sustained biochemical and virological response, assessed by qualitative PCR for viral clearance.
• Quantitative HCV RNA levels may aid in predicting treatment response, but standardized assays are needed for clinical application.
• Accurate diagnostic and confirmatory testing strategies are vital for effective hepatitis C management and treatment monitoring.